TipRanks
2 ‘Strong Buy’ penny stocks that can increase more than 100%
Bank of America has a good reputation for keeping its finger on the pulse of the financial world – and one of its most important tools is the Global Fund Manager Survey, which is conducted monthly and seeks advice from more than 200 hedge fund executives. investment funds and pension funds. which collectively owns $ 645 billion in AUM. This is the largest regular survey of its kind. And the latest findings from BofA show that Big Money feels confident. More than 90% of investors surveyed believe that 2021 will show a significant recovery from 2020, that the allocation of assets to equities and commodities is at its highest in ten years, and that overall growth believes that it is a highlight of all time. So there is general consensus that now is the time to invest. The only remaining question is, invest in what? Wall Street proponents argue that there are early companies that reflect promising opportunities, with low stock prices meaning you have significantly more money for it. What’s more, even what appears to be a slight increase in the share price can result in large percentage gains. The conclusion? Not all risks are equated. For this purpose, the benefits recommend that you do careful research before making an investment decision. To this end, we used the TipRanks database to find compelling penny stocks with cheap price tags. The platform led us in the direction of two indicative prices that had the share prices below $ 5 and ‘Strong Buy’ consensus ratings from the analyst community. Not to mention the significant upside potential is on the table. ObsEva SA (OBSV) First up is a clinical condition biopharmaceutical company with a sharp focus on women’s health. ObsEva is working on the development and commercialization of new drugs for female reproductive health issues – up to and including pregnancy. The company’s main drug candidate, linzagolix (branded as Yselty), is an orally administered GnRH receptor antagonist who has completed two Phase 3 studies, PRIMROSE 1 in the US and PRIMROSE 2 in both the US and Europe. The clinical trials included 574 and 535 patients, respectively, and doses of 100 mg or 200 mg were used to treat heavy menstrual bleeding associated with uterine fibroids. The results of both studies were positive, supporting Linzagolix’s favorable profile for safety and efficacy. In an update announced last month, ObsEva reported that the European Medicines Agency (EMA) has approved the marketing authorization (MAA) application for Yselty (100 mg and 200 mg) in accordance with Phase 3 results. Potential MAA approval is expected in Q4: 21. The drug is also the subject of a new drug application (NDA) to be submitted to the FDA in the second quarter. With stocks changing for $ 3.80 apiece, Wedbush analyst Liana Moussatos sees an attractive entry point for investors. “In our opinion, Linzagolix has the potential to achieve the best oral GnRH receptor antagonist status, based on a flexible dosing regimen with or without adjuvant hormone therapy (ABT) – an important distinction from other GnRH receptor antagonists … Based on the positive PRIMROSE 1 and PRIMROSE 2 primary endpoint results for YSELTY® / UF and additional follow-up data, we plan an annual sales of more than $ 750 million in 2027 for Linzagolix / UF, ”says Moussatos. Moussatos rates OBSV a buy with a price target of $ 28. If her dissertation plays out, a potential twelve-month profit could be ~ 643% in the card. (Click here to see Moussatos’ record.) Overall, ObsEva impressed its observers, as evidenced by the unanimous consensus rating of the strong buy on the stock, based on three recent buy reviews. With a return potential of 342%, the consensus price target of the stock stands at $ 16.67. (See OBSV stock analysis on TipRanks) BELLUS Health (BLU) The second stock we are looking at, BELLUS Health, is also a clinical stage of biopharma research business – but here we focus on an issue few of us ever think about . Hypersensitivity – the situation that it is sensitive to environmental or foreign stimuli – or even excessive – can cause various conditions, from chronic cough to severe disorders. Sometimes less severe chronic symptoms can be the worst. Chronic cough and chronic pruritus (itchy skin) are mild to moderate symptoms that can be caused by various factors, but if the symptoms do not go away, it can affect the quality of life excessively negatively. BELLUS ‘main drug candidate, BLU-5937, is undergoing studies on its effectiveness in treating these symptoms. BLU-5937 is a highly selective PsX3 antagonist that acts on the P2X3 receptor in the cough reflex pathway. The current clinical trial is a Phase 2b study, following the Phase 2 RELIEF trial. The RELIEF study enrolled 68 patients in the US and UK, of which 52 completed two trial periods. The trial showed a statistically significant reduction in cough score in patients with a higher baseline score. The Phase 2b studies are now enrolling and dosing patients, with interim results expected through the year, and the best results are expected to be published in the fourth quarter. RBC Capital analyst Gregory Renza’s praise is the praise of the healthcare name. ‘With a proven MOA of the clinically successful P2X3 antagonist vaccine (HRC), we believe that the high selectivity of BLU-5937 can lead to minimal taste effects and higher patient satisfaction and preference as gefapixant, where we, if successful, estimate revenue so early . as2024 with more than $ 900 million a peak global sales potential in RCC with the increase in potential label expansion to indications linked to P2X3 hypersensitivity, “Renza noted.” Despite the PE failure of the ph.II trial in RCC , we believe that the reduction in statistics in the waking cough frequency in patients with high baseline POC and viability of the asset showed. “It should therefore come as no surprise that Renza joined the bulls. Along with a better performance rating, the analyst gives the stock a price target of $ 8. This target carries his confidence in BLU’s ability to increase ~ 116% in the next twelve months (To see Renza’s record, click here.) If we look at the rest of the street now, other analysts also like what they see, with 3 buying and no holding or selling, the word on the street is that BLU is a strong buy, at $ 8.67 the average price target on the upward potential of ~ 134%. (See BLU stock- analysis on TipRanks) Visit TipRanks ‘best stocks to buy, a newly launched tool that unites all of TipRanks’ shares of the stock, to find great ideas for penny stocks at attractive valuations. Disclaimer: The opinions expressed in this article are solely those of the proposed analysts. The content is for informational purposes only. It is very important to do your own analysis before investing.